Stroke and altered mental state increase risk of death for COVID-19 patients medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
New York, Dec 19 (PTI) People hospitalised with COVID-19 and neurological problems including stroke and confusion, have a higher risk of dying than other patients infected with the novel coronavirus, according to a new study. The research, published in the journal Neurology the medical journal of the American Academy of Neurology assessed data from 4,711 COVID-19 patients who were admitted to the Montefiore Medical Center in the US during the six-week period between March 1, 2020 and April 16, 2020. According to the scientists, including those from Albert Einstein College of Medicine in the US, 581 of the 4,711 patients had neurological problems serious enough to warrant brain imaging.
Drug Siponimod Improves Thinking Speed in Multiple Sclerosis by Pooja Shete on December 18, 2020 at 7:09 PM
The study was published in the journal
Neurology, the medical journal of American Academy of Neurology.
Multiple sclerosis (MS) is neurodegenerative which affects the person s thinking skills.
Multiple sclerosis is one of the most common demyelinating disease and is commonly seen in high income countries.
Cognitive processing speed is the amount of time taken by a person to take in information, process it, and then react to complete a task. It can affect different aspects of daily life including driving skills, social activities, and employment.
E-Mail
December 18, 2020 (BRONX, NY) People hospitalized with COVID-19 and neurological problems including stroke and confusion, have a higher risk of dying than other COVID-19 patients, according to a study published online today by researchers at Montefiore Health System and Albert Einstein College of Medicine in the journal
Neurology®, the medical journal of the American Academy of Neurology. These findings have the potential to identify and focus treatment efforts on individuals most at risk and could decrease COVID-19 deaths.
The study looked at data from 4,711 COVID-19 patients who were admitted to Montefiore during the six-week period between March 1, 2020 and April 16, 2020. Of those patients, 581 (12%) had neurological problems serious enough to warrant brain imaging. These individuals were compared with 1,743 non-neurological COVID-19 patients of similar age and disease severity who were admitted during the same period.
4.7 (12)
Mayzent (siponimod) significantly improved cognitive processing speed in people with secondary progressive multiple sclerosis (SPMS) compared with a placebo, according to additional analyses of two-year data from the EXPAND Phase 3 trial.
While no approved therapies in the U.S. currently target cognitive impairment in MS, “our study found that [Mayzent], which is prescribed to slow the progression of physical disability in MS, may also help improve cognitive processing speed in people with advanced MS,” Ralph H. B. Benedict, PhD, the study’s first author, said in a press release.
Benedict is a professor of neurology at the University of Buffalo in New York, and a member of the American Academy of Neurology.